| 4.065 0.065 (1.63%) | 09-14 10:53 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.92 | 1-year : | 5.24 |
| Resists | First : | 4.22 | Second : | 4.48 |
| Pivot price | 4.12  |
|||
| Supports | First : | 3.78 | Second : | 3.14 |
| MAs | MA(5) : | 4.09 |
MA(20) : | 4.12 |
| MA(100) : | 4.03 |
MA(250) : | 2.79 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 21.9 |
D(3) : | 28.4 |
| RSI | RSI(14): 49.3 |
|||
| 52-week | High : | 5.07 | Low : | 1.28 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ MGNX ] has closed above bottom band by 43.5%. Bollinger Bands are 44.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 22 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.09 - 4.12 | 4.12 - 4.14 |
| Low: | 3.85 - 3.88 | 3.88 - 3.91 |
| Close: | 3.96 - 4 | 4 - 4.04 |
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Wed, 09 Sep 2026
MacroGenics: Inexpensive ADC/TCE Biotech With Multiple Catalysts Ahead (NASDAQ:MGNX) - seekingalpha.com
Wed, 09 Sep 2026
MacroGenics (MGNX) Institutional Ownership 2026 - marketbeat.com
Thu, 20 Aug 2026
Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Tue, 18 Aug 2026
MacroGenics (MGNX) exec adds 40K shares via option exercise - Stock Titan
Mon, 17 Aug 2026
MacroGenics (NASDAQ: MGNX) insider lines up new stock sale after recent trade - Stock Titan
Fri, 14 Aug 2026
Can MacroGenics (MGNX) Turn Gilead Sciences (GILD)’s $10M Milestone Into a Major Pipeline Catalyst? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 64 (M) |
| Shares Float | 57 (M) |
| Held by Insiders | 3.4 (%) |
| Held by Institutions | 77.5 (%) |
| Shares Short | 7,260 (K) |
| Shares Short P.Month | 5,690 (K) |
| EPS | -1.6 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.67 |
| Profit Margin | -8.4 % |
| Operating Margin | -42.2 % |
| Return on Assets (ttm) | -8.1 % |
| Return on Equity (ttm) | -225.9 % |
| Qtrly Rev. Growth | 378 % |
| Gross Profit (p.s.) | -0.03 |
| Sales Per Share | 2.74 |
| EBITDA (p.s.) | -0.51 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -64 (M) |
| Levered Free Cash Flow | -69 (M) |
| PE Ratio | -2.58 |
| PEG Ratio | 0 |
| Price to Book value | 6.11 |
| Price to Sales | 1.48 |
| Price to Cash Flow | -4.1 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|